Andrx loratadine approval
This article was originally published in The Tan Sheet
Executive Summary
FDA approves Abbreviated New Drug Application for 10 mg loratadine orally disintegrating tablets, Andrx Corporation announces Nov. 4. The tablets are bioequivalent to Schering-Plough's Claritin RediTabs. Perrigo already markets Andrx's generic versions of Claritin D24 and Claritin RediTabs. Andrx is one of at least three companies facing suits filed by Schering-Plough arguing that the firms violated certain patent claims for Clarinex (desloratadine). A Washington, D.C. federal appeals court recently upheld a D.C. appeals court decision ruling that manufacturers of generic Claritin were not infringing on those claims (1"The Tan Sheet" Nov. 3, 2003, p. 4)...
You may also be interested in...
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
A Washington, D.C. federal appeals court ruling not to rehear Schering-Plough's adverse desloratadine patent infringement decision en banc could hold serious implications for future new drugs and biologics, two dissenting judges argue
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.